Professor Bridget A. Robinson

Journal - Research Article

Patel, V., James, M., Frampton, C., Robinson, B., Davey, V., & Timmings, L. (2019). Body mass index and outcomes in breast cancer treated with breast conservation. International Journal of Radiation Oncology, Biology, Physics. Advance online publication. doi: 10.1016/j.ijrobp.2019.09.049

Wohlrab, C., Kuiper, C., Vissers, M. C. M., Phillips, E., Robinson, B. A., & Dachs, G. U. (2019). Ascorbate modulates the hypoxic pathway by increasing intracellular activity of the HIF hydroxylases in renal cell carcinoma cells. Hypoxia, 7, 17-31. doi: 10.2147/hp.S201643

Lattimore, V. L., Pearson, J. F., Morley-Bunker, A. E., kConFab Investigators, Spurdle, A. B., Robinson, B. A., Currie, M. J., & Walker, L. C. (2019). Quantifying BRCA1 and BRCA2 mRNA isoform expression levels in single cells. International Journal of Molecular Sciences, 20(3), 693. doi: 10.3390/ijms20030693

Campbell, E. J., Dachs, G. U., Morrin, H. R., Davey, V., Robinson, B. A., & Vissers, M. C. M. (2019). Activation of the hypoxia pathway in breast cancer tissue and patient survival are inversely associated with tumor ascorbate levels. BMC Cancer, 19, 307. doi: 10.1186/s12885-019-5503-x

Richardson, A. K., Walker, L. C., Cox, B., Rollag, H., Robinson, B. A., Morrin, H., Pearson, J. F., … Currie, M. J. (2019). Breast cancer and cytomegalovirus. Clinical & Translational Oncology. Advance online publication. doi: 10.1007/s12094-019-02164-1

Dixit, A., Frampton, C., Davey, V., Robinson, B., & James, M. (2019). Radiation treatment in early stage triple-negative breast cancer in New Zealand: A national database study. Journal of Medical Imaging & Radiation Oncology. Advance online publication. doi: 10.1111/1754-9485.12933

Gibbs, P., Heinemann, V., Sharma, N. K., Taieb, J., Ricke, J., Peeters, M., … Robinson, B., Jackson, C., … for the SIRFLOX and FOXFIRE Global Trial Investigators, including Perez, D. (2018). Effect of primary tumor side on survival outcomes in untreated patients with metastatic colorectal cancer when selective internal radiation therapy is added to chemotherapy: Combined analysis of two randomized controlled studies. Clinical Colorectal Cancer, 17(4), e617-e629. doi: 10.1016/j.clcc.2018.06.001

Robinson, B., Dijkstra, B., Davey, V., Tomlinson, S., & Frampton, C. (2018). Adherence to adjuvant endocrine therapy in Christchurch women with early breast cancer. Clinical Oncology, 30(1), e9-e15. doi: 10.1016/j.clon.2017.10.015

James, M., Dixit, A., Robinson, B., Frampton, C., & Davey, V. (2018). Outcomes for patients with non-metastatic triple-negative breast cancer in New Zealand. Clinical Oncology. Advance online publication. doi: 10.1016/j.clon.2018.09.006

James, M., Swadi, S., Yi, M., Johansson, L., Robinson, B., & Dixit, A. (2018). Ischaemic heart disease following conventional and hypofractionated radiation treatment in a contemporary breast cancer series. Journal of Medical Imaging & Radiation Oncology, 62(3), 425-431. doi: 10.1111/1754-9485.12712

Buchwald, P., Hall, C., Davidson, C., Dixon, L., Dobbs, B., Robinson, B., & Frizelle, F. (2018). Improved survival for rectal cancer compared to colon cancer: The four cohort study. ANZ Journal of Surgery, 88(3), E114-E117. doi: 10.1111/ans.13730

Lawrence, B., Blenkiron, C., Parker, K., Tsai, P., Fitzgerald, S., Shields, P., … Black, M., … Robinson, B., … Carroll, R., … Morrin, H., … Jackson, C., … Print, C. (2018). Recurrent loss of heterozygosity correlates with clinical outcome in pancreatic neuroendocrine cancer. npj Genomic Medicine, 3, 18. doi: 10.1038/s41525-018-0058-3

Wohlrab, C., Vissers, M. C. M., Phillips, E., Morrin, H., Robinson, B. A., & Dachs, G. U. (2018). The association between ascorbate and the hypoxia-inducible factors in human renal cell carcinoma requires a functional von Hippel-Lindau protein. Frontiers in Oncology, 8, 574. doi: 10.3389/fonc.2018.00574

Lattimore, V. L., Pearson, J. F., Currie, M. J., Spurdle, A. B., kConFab Investigators, Robinson, B. A., & Walker, L. C. (2018). Investigation of experimental factors that underlie BRCA1/2 mRNA isoform expression variation: Recommendations for utilising targeted RNA sequencing to evaluate potential spliceogenic variants. Frontiers in Oncology, 8, 140. doi: 10.3389/fonc.2018.00140

James, M., McLean, G., Williams, S., Robinson, B., & Yi, M. (2018). Complications of curative radiation treatment for early prostate cancer. Asia-Pacific Journal of Clinical Oncology, 14(5), e392-e398. doi: 10.1111/ajco.12839

Robinson, B., Currie, M., Phillips, E., Dachs, G., Strother, M., Morrin, H., Davey, V., & Frampton, C. (2017). Body mass index (BMI): Association with clinicopathological factors and outcome of women with newly diagnosed breast cancer in New Zealand. New Zealand Medical Journal, 130(1451), 46-56. Retrieved from https://www.nzma.org.nz/journal

Fernando, C., Frizelle, F., Wakeman, C., Frampton, C., & Robinson, B. (2017). Colorectal multidisciplinary meeting audit to determine patient benefit. ANZ Journal of Surgery, 87(11), E173-E177. doi: 10.1111/ans.13366

James, M. L., Dehn, G., & Robinson, B. A. (2016). Hypofractionated radiation treatment in early breast cancer: Results in a New Zealand setting. Asia-Pacific Journal of Clinical Oncology, 12, 248-253. doi: 10.1111/ajco.12458

van Hazel, G. A., Heinemann, V., Sharma, N. K., Findlay, M. P. N., Ricke, J., Peeters, M., Perez, D., Robinson, B. A., … Gibbs, P. (2016). SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 34(15), 1723-1731. doi: 10.1200/JCO.2015.66.1181

Campbell, E. J., Vissers, M. C. M., Wohlrab, C., Hicks, K. O., Strother, R. M., Bozonet, S. M., Robinson, B. A., & Dachs, G. U. (2016). Pharmacokinetic and anti-cancer properties of high dose ascorbate in solid tumours of ascorbate-dependent mice. Free Radical Biology & Medicine, 99, 451-462. doi: 10.1016/j.freeradbiomed.2016.08.027

Campbell, E. J., Vissers, M. C. M., Bozonet, S., Dyer, A., Robinson, B. A., & Dachs, G. U. (2015). Restoring physiological levels of ascorbate slows tumor growth and moderates HIF-1 pathway activity in Gulo^−/− mice. Cancer Medicine, 4(2), 303-314. doi: 10.1002/cam4.349

Dachs, G. U., Phillips, E., Phung, Y., Dyer, A., Willis, J. A., Currie, M. J., & Robinson, B. A. (2015). Tumour growth in mice resistant to diet-induced obesity. Journal of Molecular Biochemistry, 4(2), 42-49.

Kuchenbaecker, K. B., Ramus, S. J., Tyrer, J., Lee, A., Shen, H. C., Beesley, J., … kConFab, including Gardner, M., George, P., Kidd, A., Reeve, T., Robinson, B., Walker, L., … for the Consortium of Investigators of Modifiers of BRCA1 and BRCA2. (2015). Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 47(2), 164-171. doi: 10.1038/ng.3185

Price, T. J., Bruhn, M. A., Lee, C. K., Hardingham, J. E., Townsend, A. R., Mann, K. P., … Robinson, B., … Tebbutt, N. C. (2015). Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX study involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. British Journal of Cancer, 112, 963-970. doi: 10.1038/bjc.2015.37

Gerring, Z., Pearson, J. F., Morrin, H. R., Robinson, B. A., Harris, G. C., & Walker, L. C. (2015). Phosphohistone H3 outperforms Ki67 as a marker of outcome for breast cancer patients. Histopathology, 67(4), 538-547. doi: 10.1111/his.12678

Ko, D.-H. I., Norriss, A., Harrington, C. R., Robinson, B. A., & James, M. L. (2015). Hypofractionated radiation treatment following mastectomy in early breast cancer: The Christchurch experience. Journal of Medical Imaging & Radiation Oncology, 59, 243-247. doi: 10.1111/1754-9485.12242

Michailidou, K., Beesley, J., Lindstrom, S., Canisius, S., Dennis, J., Lush, M. J., … kConFab, including Gardner, M., George, P., Kidd, A., Reeve, T., Robinson, B., Walker, L., … Easton, D. F. (2015). Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nature Geoscience, 47, 373-380. doi: 10.1038/ng.3242

Richardson, A. K., Currie, M. J., Robinson, B. A., Morrin, H., Phung, Y., Pearson, J. F., … Walker, L. C. (2015). Cytomegalovirus and Epstein-Barr Virus in breast cancer. PLoS ONE, 10(2), e0118989. doi: 10.1371/journal.pone.0118989

Perry, J. R. B., Day, F., Elks, C. E., Sulem, P., Thompson, D. J., Ferreira, T., … kConFab, including Gardner, M., George, P., Kidd, A., Reeve, T., Robinson, B., Walker, L., … Ong, K. K. (2014). Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. Nature, 514, 92-97. doi: 10.1038/nature13545

Valle, J. W., Palmer, D., Jackson, R., Cox, T., Neoptolemos, J. P., Ghaneh, P., … Robinson, B. A., … Büchler, M. W. (2014). Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: Ongoing lessons from the ESPAC-3 study. Journal of Clinical Oncology, 32, 504-512. doi: 10.1200/JCO.2013.50.7657

Volkova, E., Robinson, B. A., Willis, J., Currie, M. J., & Dachs, G. U. (2014). Marginal effects of glucose, insulin and insulin-like growth factor on chemotherapy response in endothelial and colorectal cancer cells. Oncology Letters, 7(2), 311-320. doi: 10.3892/ol.2013.1710

Jackson, C. G. C. A., Sharples, K., Thompson, P. I., O'Donnell, A., Robinson, B. A., Perez, D. J., … Findlay, M. P. (2014). Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: A multi-centre phase II study. BMC Cancer, 14, 737. doi: 10.1186/1471-2407-14-737

Davey, V. C. L., Harris, G., Dijkstra, B., James, M., & Robinson, B. (2014). A review of the Christchurch Hospital Breast Cancer Service in 2012: Meeting the new Tumour Standards. New Zealand Medical Journal, 127(1399). Retrieved from http://www.nzma.org.nz/journal

Kuiper, C., Dachs, G. U., Munn, D., Currie, M. J., Robinson, B. A., Pearson, J. F., & Vissers, M. C. M. (2014). Increased tumour ascorbate is associated with extended disease-free survival and decreased hypoxia-inducible factor-1 activation in human colorectal cancer. Frontiers in Oncology, 4, 10. doi: 10.3389/fonc.2014.00010

Morrin, H. R., & Robinson, B. A. (2013). Sustaining a biobank through a series of earthquake swarms: Lessons learned from our New Zealand experience. Biopreservation & Biobanking, 11(4), 211-215. doi: 10.1089/bio.2013.0033

Bidwell, S., Simpson, A., Sullivan, R., Robinson, B., Thomas, W., Jackson, C., … Clarke, T. (2013). A workforce survey of New Zealand medical oncologists. New Zealand Medical Journal, 126(1371). Retrieved from http://www.nzma.org.nz/journal

Walker, L. C., McDonald, M., Wells, J. E., Harris, G. C., Robinson, B. A., & Morris, C. M. (2013). Dual-color fluorescence in situ hybridization reveals an association of chromosome 8q22 but not 8p21 imbalance with high grade invasive breast carcinoma. PLoS ONE, 8(7), e70790. doi: 10.1371/journal.pone.0070790

Lim, M., Sharma, P., Ing, A., Blackburne, H., Robinson, B., Dixon, L., Frampton, C., & Frizelle, F. (2013). Continued progress with stage III colorectal cancer: A triple cohort study. New Zealand Medical Journal, 126(1382). Retrieved from http://www.nzma.org.nz/journal

Edwards, A. L., Gunningham, S. P., Clare, G. C., Hayman, M. W., Smith, M., Frampton, C. M. A., Robinson, B. A., Troughton, R. W., & Beckert, L. E. L. (2013). Professional killer cell deficiencies and decreased survival in pulmonary arterial hypertension. Respirology, 18(8), 1271-1277. doi: 10.1111/resp.12152

Currie, M. J., Beardsley, B. E., Harris, G. C., Gunningham, S. P., Dachs, G. U., Dijkstra, B., Morrin, H. R., Wells, J. E., & Robinson, B. A. (2013). Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: Relationships with markers of tumor hypoxia and microvascularity. Human Pathology, 44(3), 402-411. doi: 10.1016/j.humpath.2012.06.004

Price, T. J., Zannino, D., Wilson, K., Simes, R. J., Cassidy, J., van Hazel, G. A., Robinson, B. A., … Tebbutt, N. C. (2012). Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: A subgroup analysis from the AGITG MAX trial: An international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C. Annals of Oncology, 23(6), 1531-1536. doi: 10.1093/annonc/mdr488

Hock, B. D., Mackenzie, K. A., Cross, N. B., Taylor, K. G., Currie, M. J., Robinson, B. A., Simcock, J. W., & McKenzie, J. L. (2012). Renal transplant recipients have elevated frequencies of circulating myeloid-derived suppressor cells. Nephrology Dialysis Transplantation, 27(1), 402-410. doi: 10.1093/ndt/gfr264

Hunt, M. A., Li, D., Hay, M. P., Currie, M. J., Robinson, B. A., Patterson, A. V., & Dachs, G. U. (2012). Characterisation of enzyme prodrug gene therapy combinations in coated spheroids and vascular networks in vitro. Journal of Gene Medicine, 14(1), 62-74. doi: 10.1002/jgm.1635

Davey, V., Robinson, B., Dijkstra, B., & Harris, G. (2012). The Christchurch Breast Cancer Patient Register: The first year. New Zealand Medical Journal, 125(1360). Retrieved from http://www.nzma.org.nz/journal

Volkova, E., Willis, J. A., Wells, J. E., Robinson, B. A., Dachs, G. U., & Currie, M. J. (2011). Association of angiopoietin-2, C-reactive protein and markers of obesity and insulin resistance with survival outcome in colorectal cancer. British Journal of Cancer, 104, 51-59. doi: 10.1038/sj.bjc.6606005

Zhi, J., Chen, E., Major, P., Burns, I., Robinson, B., McKendrick, J., … Goldstein, D. (2011). A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer. Cancer Chemotherapy & Pharmacology, 68(5), 1199-1206. doi: 10.1007/s00280-011-1606-z

MacKenzie, K. A., Miller, A. P., Hock, B. D., Gardner, J., Simcock, J. W., Roake, J. A., Dachs, G. U., Robinson, B. A., & Currie, M. J. (2011). Angiogenesis and host immune response contribute to the aggressive character of non-melanoma skin cancers in renal transplant recipients. Histopathology, 58(6), 875-885. doi: 10.1111/j.1365-2559.2011.03845.x

Tebbutt, N. C., Wilson, K., Gebski, V. J., Cummins, M. M., Zannino, D., van Hazel, G. A., Robinson, B., … Price, T. J. (2010). Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study. Journal of Clinical Oncology, 28(19), 3191-3198. doi: 10.1200/JCO.2009.27.7723